Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100°C

Biologicals

Volumn 24, Issue 2, 1996, Pages 125-130

  Dichtelmuller H ^a   Rudnick, D ^a   Breuer, B ^a   Kotitschke, R ^a   Kloft, M ^a   Darling, A ^b   Watson, E ^b   Flehmig, B ^e   Lawson, S ^c   Frosner G ^d  

^a BIOTEST AG   (Germany)

^b Q One Biotech Ltd   (United Kingdom)

^c Mediagnost   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ARTICLE; BOVINE DIARRHEA VIRUS; HEAT TOLERANCE; HEAT TREATMENT; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; PARVOVIRUS; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; REOVIRUS; SIMIAN VIRUS 40; VESICULAR STOMATITIS VIRUS; VIRUS INACTIVATION; VIRUS RESISTANCE;

BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1; HEPATITIS A VIRUS; HERPETOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MAMMALIAN ORTHOREOVIRUS 3; PARVO VIRUS; PARVOVIRUS; RABIES VIRUS; REOVIRUS SP.; RNA VIRUSES; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40; SUID HERPESVIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 0030175069     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1996.0016     Document Type: Article

References (38)

1. 1. Manucci PM. Outbreak of Hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819.
2. 2. Gerritzen A, Schneweis KE, Brackmann HH et al. Acute Hepatitis A in haemophiliacs. Lancet 1992; 340: 1231-1232.
3. 3. Peerlinck K, Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet 1993; 341: 179.
4. 4. Temperley IJ, Cotter KP, Walsh TJ, Power J, Hillary IB. Clotting factors and hepatitis A. Lancet 1992; 340: 31.
5. 5. Prince AM, Horowitz B, Horowitz MS, Zang E. The development of inner free labile blood derivatives - a review. Eur I Epidemiol 1987; 3: 103-118.
6. 6. Lee KK, Vargo LR, Le CT, Fernando L. Transfusion-acquired Hepatitis A outbreak from fresh frozen plasma in a neonatal intensive care unit. Pediatr Infect Dis J 1992; 11: 122-123.
7. 7. Shouval D, Gerlich WH. Clotting factors and Hepatitis A. Lancet 1992; 340: 1465-1466.
8. 8. Hollinger FB, Khan NC, Oefinger PE et al. Posttransfusion Hepatitis A. JAMA 1993; 250: 2313-2317.
9. 9. Winokur PL, Stapleton IT. Immunoglobulin Prophylaxis for hepatitis A. Clin Inf Dis 1992; 14: 580-586.
10. 10. Hamman J, Zou J, Horowitz B. Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates. Vox Sang 1994; 67 (Suppl.): 72-77.
11. 11. Mohr H, Lambrecht B, Marks F, Tschech A. Analysis of clotting factor concentrates and elimination of non-enveloped viruses in their manufacture. Vox Sang 1994; 67 (Suppl.): 78-79.
12. 12. Horowitz B, Hamm J, Lemon S et al. The American experience and removal/inactivation of Hepatitis A virus during fractionation. Abstract: Meeting of the European Plasma Factionation Association; Hepatitis A: Are Factor VIII products safe? Edinburgh, Scotland, Scottish National Blood Transfusion Service.
13. 13. Cuthbertson B. Good manufacturing practice: Avoiding opportunities for contamination. Abstract: Meeting of the European Plasma Fractionation Association; Hepatitis A: Are Factor VIII products safe? Edinburgh, Scotland, Scottish National Blood Transfusion Service.
14. 14. Richtlinien zur Blutgruppenbestimmung und Bluttransfusion des wissenschaftlichen Beirates der Bundesärztekammer und des Bundesgesundheitsamtes. Bundesgesundhbl 1992; 2: 96-106.
15. 15. Flehmig B, Heinrich N, Pfisterer M. Immunogenicity of a killed Hepatitis A vaccine in seronegative human volunteers. Lancet I 1989; 1039-1041.
16. 16. Frösner GG, Deinhardt F, Scheid R et al. Propagation of human Hepatitis A Virus in a hepatoma cell line. Infection 1979, 7: 303-306.
17. 17. Wieland G. Wasserbestimmung durch Karl Fischer Titration. GIT Verlag, Darmstadt 1985.
18. 18. Spearman C, Kaerber G. In: Bibrack B, Wittmann G, eds. Virologische Arbeitsmethoden. Stuttgart: Fischer Verlag, 1974, 37-39.
19. 19. Revised CPMP Guideline on Virus Validation Studies 1995. CPM 268/95, APPENDIX II.
20. 20. DIN 58909, Part 1; Determination of Factor VIII coagulation activity (Factor VIII C); one stage method (in German) Beuth Verlag GmbH, Berlin: Germany.
21. 21. Frösner GG, Stephan W, Dichtelmüller H. Inactivation of Hepatitis A virus added to pooled human plasma by β-propiolactone treatment and ultraviolet irradiation. Eur J Clin Microbiol 1983; 2: 355-357.
22. 22. Arrighi S, Rossi R. Lesnikov V, Lesnikova M. DeSantis ME, Bucci E. Evaluation of biochemical and immunological differences in double virus inactivated Factor VIII concentrates. Thromb Haemost 1993; 69: 538-1455. (Abstract #1456, XIVth Cong. Int Soc Throm Haem. New York).
23. 23. Kotitschke R, Dichtelmüller H, Rudnick D et al. Double virus inactivated Factor VIII concentrate: Virus validation and immunological assessment of Factor VIII SDH. Hämostaseologie 1994; 14: 100-103.
24. 24. Elödi S, Kotitschke R, Dichtelmüller H. Rudnick D, Kloft M. Double virus inactivated Factor VIII concentrate: Virus validation and clinical efficacy of haemoctin biotest. 39th Meeting of the Society for Thrombosis and Haemostasis 1995, Berlin, Germany.
25. 25. McDougal JS, Martom LS, Cort SP, Mozen M, Heldebrandt CM, Evatt BL. Thermal inactivation and the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus. J Clin Invest 1985; 76: 875-877.
26. 26. Spire B, Dormont D, Barré-Sinoussi F, Montagnier L, Chermann JC. Inactivation of lymphadenopathy-associated virus by heat, gamma rays and ultraviolet light. The Lancet 1985: 188-189.
27. 27. Peterson DA, Wolfe LG, Larkin EP, Deinhardt FW. Thermal treatment and infectivity of Hepatitis A Virus in human faeces. J Med Virol 1978; 2: 201-206.
28. 28. Arrighi S, Rossi R, Lesnikov V, Lesnikova M, DeSantis ME, Bucci E. 'In vitro' and in animal model studies on a double virus inactivated factor VIII concentrate. Thromb Haemost 1995; 74: 868-873.
29. 29. Heimburger N, Schwinn H, Gratz P, Lüben G, Kumpe G, Herschenhahn B. Faktor VIII Konzentrat, hochgereinigt und in Lösung erhitzt. Arznm Forschung/Drug Res 1981; 31: 619-622.
30. 30. Murphy P, Nowak T, Lemon SM, Hilfenhaus J. Inactivation of hepatitis A virus by heat treatment in aqueous solution. J Med Virol 1993; 41: 61-69.
31. 31. Simesen R, Kaersgaard P, Darling A, Lees G, Nielsen C. Virus inactivation and elimination during manufacturing of a very high purity Factor VIII preparation (Abstract). IABS Meeting Cannes, 1992.
32. 32. Mahnel H. Differences in resistance of viruses (in German). Infection 1979; 7: 240-244.
33. 33. Andrewes C. In: Porterfield, JS, ed. Andrewes' viruses of vertebrates; Fifth Edition, London, Baillière Tindall: 1989; 374.
34. 34. William MD, Cohen BJ, Beddall AC, Pasi KJ, Mortimer PP, Hill FGH. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang 1990; 58: 177-181.
35. 35. Schwarz TF, Parvovirus B19-Infektion Hämophilie Symposium Hamburg In: Landbeck G, Marx R, eds. Berlin: Springer Verlag, 1989; 2.
36. 36. Schwarz TF, Roggendorf M, Hottenträger B, Stolz W, Schwinn H. Removal of Parvo virus B19 from contaminated Factor VIII during fractionation. J Med Virol 1991; 35: 28-31.
37. 37. Hart HF, Hart WG, Crossley J et al. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang 1994; 67: 345-350.
38. 38. Purcell RH, Feinstone SM, Ticehurst JR, Daemer RJ, Baroudy BM. Hepatitis A virus. In: Vyas G, Dienstag JL, Hoofnagle JH, eds. Viral Hepatitis and liver disease. Orlando: Grube and Stratton, 1, 1984; 9-22.